A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Ontology highlight
ABSTRACT: This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).
DISEASE(S): Adenocarcinoma,Gastrointestinal Neoplasms,Biliary Tract Neoplasms,Colorectal Cancer,Colorectal Neoplasms,Her2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, And Colorectal Cancer
PROVIDER: 2303997 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA